UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News:
Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2015.
Positive cash flow and EBIT. Expansion of Zubsolv® to new markets and improved market access position in the US.
Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2015.
Positive cash flow and EBIT. Expansion of Zubsolv® to new markets and improved market access position in the US.
